The profiles of unconjugated pteridines such as neopterin and biopterin and of tryptophan metabolism change in many pathologic conditions such as rheumatoid arthritis, malignancies and autoimmune diseases and are related to the release of pro-inflammatory cytokines. However, studies on potential effects of drugs are very limited. This study investigates whether meloxicam, a non-steroidal anti-inflammatory drug, may cause any alteration of the pteridine pathway and tryptophan metabolism in 22 patients who admitted to the Physical and Rehabilitation Medicine outpatient clinic in the Hacettepe University Hospital and suffering from various musculoskeletal pain conditions without systemic inflammation. Urine concentrations of neopterin, biopterin and xanthopterin, and serum concentrations of neopterin, tryptophan, and kynurenine, and the activity of dihydropteridine reductase were measured at the beginning of the therapy and after a 15 days treatment with meloxicam. Average urine concentrations (± S.E.M.) of pterins before therapy (neopterin: 263 ± 15.6 µmol/mol creatinine, biopterin: 72.4 ± 13.4 µmol/mol creatinine, and xanthopterin: 675 ± 93.0 µmol/mol creatinine) were not changed during meloxicam therapy (neopterin: 230 ± 30.7 µmol/mol creatinine = 88% of baseline, biopterin 115 ± 26.5 µmol /mol creatinine = 159% of baseline, and xanthopterin 684 ± 88.0 µmol/mol creatinine = 101% of baseline; all differences not significant). The activity of dihydropteridine reductase was 6.02 ± 0.21 nmol/cytochrome C reduced/min/5 mm disc before and 6.28 ± 0.18 nmol/cytochrome C reduced/min/5 mm after treatment (= 104% of baseline; p = 0.088). Serum concentrations of neopterin 6.04 ± 0.33 nmol/L before treatment increased to 6.89 ± 0.48 nmol/L after treatment (= 114% of baseline; p <0.05, paired rank test). Likewise serum kynurenine concentrations increased from 1.52 ± 0.13 µmol/L to 1.87 ± 0.14 µmol/L after treatment (= 123% of baseline; p <0.01). There was a significant correlation between neopterin and kynurenine concentrations which corresponds with their common background of production, namely immune activation. However, also the mean tryptophan concentration in pretreatment samples 51.4 ± 3.34 increased to 59.3 ± 3.34 µmol/L post-treatment (= 115% of baseline; p <0.05). The change of kyn/trp was minor (at baseline: 30.4 ± 2.01, post-treatment: 32.2 ± 2.47 µmol/mmol; = 106% of baseline, not significant). Our findings show an influence of meloxicam treatment on neopterin and tryptophan metabolism in patients. However, significant differences were only found in serum but not in urine of patients. In serum, all marker concentrations increased including tryptophan and kynurenine.
Introduction
Meloxicam, as a non-steroidal anti-inflammatory drug (NSAID) is widely used all over the world. It is a selective cyclooxygenase (COX) inhibitor and has shown potent anti-inflammatory and analgesic activity in several inflammatory diseases. Meloxicam has been found to be particularly effective in immune-mediated inflammation (1) . The induction of COX-2 by inflammatory stimuli, cytokines or lipopolysaccharides has been demonstrated not only in macrophages but also in endothelial cells and synoviocytes (2) .
The unconjugated pteridines are a group of heterocyclic compounds derived from the nucleotide guanosine triphosphate (GTP) and are known to exert a variety of biological actions (3) (4) (5) (6) . Th1-type cytokine interferon-gamma (IFN-γ) stimulates GTP-cylohydrolase, the key-enzyme in the biosynthesis of pteridines, in various cells and species and initiates the production of 5,6,7,8-tetrahydrobiopterin. Due to a deficiency of 6-pyrovuyl-tetrahydropterin synthase in human and primate monocyte-derived macrophages and dendritic cells, they release neopterin at the expense of biopterin derivatives. Therefore, the neopterin concentration in human and primate body fluids can serve as a sensitive marker of immune activation (7) . In parallel, IFN-γ stimulates the enzyme indoleamine (2,3)-dioxygenase (IDO), which degrades tryptophan (trp) to form as first catabolites N-formyl kynurenine and kynurenine (kyn), which mostly in the liver are subsequently converted to niacin as end products (8) (9) (10) . The ratio of serum kynurenine to tryptophan concentrations (kyn/trp) allows an estimate of IDO activity (8) . The elevation of neopterin levels or tryptophan degradation in body fluids is highly correlated with the severity of the diseases and the outcome and survival of the patients (11) (12) (13) (14) (15) (16) .
The group of unconjugated pteridines includes, among others, biopterin and tetrahydrobiopterin, neopterin, and their catabolite xanthopterin. Neopterin, biopterin and xanthopterin concentrations have been found to be elevated in patients with cancer, chronic infections, connective tissue disorders, and also renal failure (7, (11) (12) (13) (14) (15) 17) . Tetrahydrobiopterin is an essential cofactor responsible for the hydroxylation of the aromatic amino acids and thus involved in the synthesis and regulation of neurotransmitters, mammalian aromatic amino acid monooxygenases, oxidative cleavage of ether lipids and nitric oxide production (12, 18, 19) . Aromatic amino acid monooxygenases regulate the biosynthesis of neurotransmitters, dopamine, noradrenaline, epinephrine and serotonin by hydroxylating phenylalanine, tyrosine and tryptophan. During enzyme reactions, tetrahydrobiopterin is converted to the quinonoid dihydrobiopterin, and subsequently it is mainly regenerated by the enzyme dihydropteridine reductase (DHPR). A block in the tetrahydrobiopterin pathway leads to the accumulation of phenylalanine and to the altered production of neurotransmitters and may cause severe neurological illness (18) (19) (20) . It has been recognized that many diseases, some drugs, and xenobiotics may cause changes in tetrahydrobiopterin concentration and/or DHPR enzyme activity (12, 20) .
Several pteridines have biological activity and are increased in the blood or urine in various disease states, especially those associated with lymphocyte activation and proliferation (7, 14, 21) . The major aim of the present study was to compare DHPR activity, pterin production and tryptophan degradation in patients suffering from various degenerative diseases and to investigate the potential effect of meloxicam.
Materials and methods

Subjects and samples
Twenty two consecutive patients (17 females, 5 males) who admitted to Physical and Rehabilitation Medicine outpatient clinic of Hacettepe University Hospital, suffering from osteoarthritis (8 patients), tendinitis (6 patients), nonspecific low back pain (4 patients), plantar fasciitis with epin calcanei (2 patients), carpal tunnel syndrome (1 patient) and bursitis (1 patient) were included in the study after receiving their oral informed consent. Mean age of the patients was 50.6 years (range 36-74 years). Patients with systemic inflammatory or malignant diseases were excluded from the study. None of them were taking any medication during last 3 months other than antihypertensive drugs (3 patients), statins (2 patients), diltiazem (1 patient) and L-thyroxine (1 patient). Patients used meloxicam 7.5 mg/day for 15 days.
Fasting blood and urine samples were collected between 8:30 -10:00 AM at the baseline and after 15 days of the treatment. The study was approved by the local ethics committee of Hacettepe University to be in concordance with the Helsinki Declaration, 1981.
Blood samples were drawn into vaccutainer tubes and centrifuged for 10 min at 3000 rpm at 4°C. Both urine and serum samples were kept away from direct light, and stored at -20°C until assayed. Blood drops were simultaneously collected before and after treatment and the specimens were also stored at the same conditions until the enzyme activity assay was performed.
Measurements
Urinary neopterin, biopterin and xanthopterin levels were analyzed by high performance liquid chromatography (HPLC) as described before (4, 22, 23) . Creatinine concentrations were determined simultaneously by using an ultraviolet detector at the wavelength of 235 nm (22) . Urinary pteridine concentrations were given as mol pterin per mol creatinine.
Serum neopterin concentrations were measured by ELISA (BRAHMS, Hennigsdorf, Berlin, Germany) according to manufacturers' instructions. Serum tryptophan and serum kynurenine concentrations were determined by HPLC on reversed phase. L-kynurenine was monitored by its UV-absorption at 360 nm, tryptophan by detection of its natural fluorescence at 285 nm excitation and 365 nm emission wavelengths. 3-nitro-L-tyrosine was used as an internal standard (24), kyn/trp was calculated.
Using dried blood drops on a filter paper, the changes in DHPR activity were measured at 550 nm wavelength at room temperature with a spectrophotometric method based on reduction of ferricytochrome C in presence of NADH (12, 20) . DHPR activity was expressed as nanomoles of cytochrome C reduced per minute relative to the 5 mm diameter of blood spots.
Statistical analysis
All results were expressed as mean standard error of the mean (SEM). The comparison between the dependent groups was performed by Wilcoxon pairedsamples test, and correlations among the detected parameters were tested for by Spearman rank correlation analysis. P-values <0.05 were considered to indicate statistical significance.
Results
At baseline, mean value of urine neopterin concentrations was 263 ± 15.6 µmol/mol creatinine decreased slightly after treatment (not significant; Table 1 and Fig. 1 ). The average concentration of biopterin was 72.4 ± 13.4 µmol/mol creatinine before any therapy and it increased to 115 ± 26.5 µmol/mol creatinine post-treatment (not significant). Average urine concentration of xanthopterin was 675 ± 93.0 µmol/mol creatinine before and remained quite stable after treatment (not significant; Table 1 and Fig. 1) .
The mean serum neopterin was 6.04 ± 0.33 nmol/L before treatment and increased after treatment (p <0.05; Table 1 and Fig. 2) . Mean values of serum tryptophan and kynurenine concentrations at baseline (tryptophan: 51.4 ± 3.34 µmol/L; kynurenine: 1.52 ± 0.13 µmol/L) increased after treatment (p <0.05 and p <0.01, respectively; Table 1 and Fig. 2 ). Kyn/trp only slightly increased from 30.4 ± 2.01 at baseline to 32.2 ± 2.47 µmol/mmol after 15 days (p = 0.082).
Before treatment with meloxicam the activity of enzyme DHPR was 6.02 ± 0.21 nmol/cytochrome C reduced/min/5 mm disc and it increased to 6.28 ± 0.18 nmol/cytochrome C reduced/min/5 mm disc in patients on meloxicam. The difference did not quite reach the level of significance (p = 0.088).
At baseline, there were positive correlations between serum neopterin and serum kynurenine concentrations (r s = 0.840, p <0.001) and kyn/trp (r s = 0.497, p <0.05), and also urinary neopterin concentrations correlated with serum kyn/trp (r s = 0.467, p <0.05). Serum neopterin at baseline correlated with urinary neopterin at day 15 (r s = 0.643, p <0.01) but not at baseline. Serum kynurenine concentrations at baseline correlated with levels measured at day 15 of urinary neopterin (r s = 0.682, p = 0.001), and serum phan levels before treatment (r s = 0.550, p <0.05). There was a significant correlation between DHPR and biopterin (r s = -0.554, p = 0.032) while the correlation between DHPR and neopterin was not significant (r s = -0.124, p = 0.700). Among all other variables there were no significant correlations observed between samples measured before and after therapy.
Discussion
In the present study some aspects of pteridine and tryptophan metabolic pathways were evaluated in patients suffering from degenerative diseases like osteoarthritis, tendinitis, low back pain, plantar fasciitis, carpal tunnel syndrome and bursitis. This study gave special attention to possible effects of short term treatment with meloxicam on the immunobiological pathways. Neopterin levels in body fluids are valuable indicators of the degree of cellular immune activation and also oxidative stress. It is well known that neopterin levels show considerable alteration in various diseases such as autoimmune and inflammatory diseases, virus infections and cancer (7) . Its secretion has been correlated with the release of superoxide radicals (4, 5, 21) , and higher blood neopterin concentrations were found to correlate with the decline of several antioxidants in patients with coronary heart disease (25) . The urinary neopterin levels were only slightly, but non-significantly, higher after treatment than they before treatment. By contrast, the mean serum neopterin concentration was significantly higher on 15th day of the treatment. One might expect that the anti-inflammatory properties of meloxicam would exert a decreasing rather than increasing effect on neopterin levels. However, the opposite was the case and we assume that it may originate from inflammation, independent from meloxicam therapy. Nevertheless, meloxicam did not cause any decrease in parameters related with pteridine pathway, unlike we expected. It is too early to answer these obscure points. After treatment also higher kynurenine levels were observed, in parallel to the increase of serum neopterin levels, and there existed a positive correlation between serum neopterin and kynurenine levels before the treatment. The kynurenine pathway is constitutively active in the liver, and a basal kynurenine concentration of 1.92 ± 0.58 µmol/L can be found in healthy individuals (24) . However, the strong correlation found between neopterin and kynurenine concentrations and kyn/trp at baseline suggests that also the baseline kynurenine concentrations are related to the immune activation status and less strongly influenced by hepatic tryptophan pyrrolase. Moreover, under inflammatory conditions, when IFN-γ production is increased, IDO is stimulated and increased tryptophan degradation occurs, which leads to increased kynurenine and to decreased tryptophan concentration in serum (8, 26) .
Tryptophan is an essential amino acid, inadequate dietary intake leading to a negative nitrogen balance and to a loss of muscle mass and weight. Besides, tryptophan is a precursor for a series of metabolic reactions. It is a constituent of proteins and in parallel it represents a source for mainly two pivotal biochemical pathways: the generation of serotonin, and the formation of kynurenine (26) . Levels of free serum tryptophan range from 40 to 100 µmol/L and are depend to some extent from dietary intake. In the present study, it was found that treatment with meloxicam caused an increase in serum tryptophan levels. Reasons of this case may be either diet of the patients or effects of meloxicam against its degradation, but, this point remains unclear. From the relatively unchanged kyn/trp levels at baseline and after meloxicam administration it appears that any suppression of immunity cannot explain the increase of tryptophan levels. Since concentrations of all 3 compounds measured in serum, namely neopterin, kynurenine and tryptophan, increase in parallel, the observation could relate to an effect of meloxicam to reduce their renal clearance. However, no relevant influence of meloxicam on, e.g., creatinine clearance has been reported (27) . After a 7-day period application of meloxicam to beagle dogs, the influence on creatinine concentrations and other renal function parameters was only minor (28) .
Biopterin is also a major product among unconjugated pteridines and is more stable and detectable in biological fluids than tetrahydrobiopterin (20) . Still we did not observe any significant change of mean biopterin levels and DHPR activity (4) during meloxicam administration. Xanthopterin concentrations were broadly scattered in the specimens of patients before and after treatment with meloxicam. The accumulation of xanthopterin in urine specimens is usually considered to indicate breakdown of 6-substituted 7,8-dihydropteridine derivatives, which could explain their broad scattering of xanthopterin concentrations in our patients. And why xanthopterin concentrations did not correlate with neopterin or biopterin levels. Bakir et al. showed that elevated xanthopterin caused immune suppression in cell cultures (21) . In addition, xanthopterin itself, through an end product suppresses the proliferation and growth of stimulated lymphocytes and inhibits RNA synthesis in vitro (21) . Moreover, xanthopterin is a potent substrate and inhibitor of xanthine oxidase which produces superoxides (29) .
In conclusion, there are conflicting data about whether meloxicam has a scavenger activity or not (30) (31) (32) (33) (34) (35) (36) (37) . According to our findings related to alterations in pteridine pathway in the present study, meloxicam treatment of 15 days period and 7.5 mg dose level does not significantly influence Th1-type immune activation. However, our study deals with patients suffering from degenerative disorders which do not strongly involve innate or adaptive immune responses at baseline. Thus, we could not expect gross changes of markers like neopterin and tryptophan degradation. Therefore, any positive treatment effect of meloxicam in such patients may not involve immune activation pathways related to Th1-type immunity.
